About Us

Dr. Carlos Cordon-Cardo

Our Founder's Story

Widely recognized as a founding figure in molecular pathology and the originator of the concept of systems pathology, Dr. Carlos Cordon-Cardo (often referred to by his initials “3C”) has pioneered an “inside-out” framework for understanding disease. His approach integrates anatomical pathology with molecular and systems biology, offering a more comprehensive perspective on disease mechanisms. Inspired by advances in technologies such as GPS (Global Positioning Systems) and AI (Artificial Intelligence), Dr. Cordon-Cardo reimagined the human body not through the traditional “outside-in” clinical lens, but through biologically informed landmarks, enabling more precise diagnostic, prognostic, and therapeutic insights. This paradigm has laid the foundation for new models of risk stratification and data-driven patient care.

Today, PreciseDx embodies the culmination of Dr. Cordon-Cardo’s decades of research, innovation, and translational impact. It reflects the convergence of academic rigor, technological innovation, and purpose-driven collaboration with commercial leaders; all united in the mission to improve patient outcomes. As a cancer survivor himself, Dr. Cordon-Cardo brings both professional expertise and personal empathy to this vision. He hopes the enduring legacy of “3C” will stand for Curiosity, Creative, and Community, values he believes are essential to transforming the future of precision medicine. At the heart of this mission is a simple but powerful commitment: “translating data into knowledge to better care for patients.”

INTERNAL

PreciseDx Management Team

PreciseBreast powers the process of diagnosis and cancer care planning for everyone.

Eric Converse

chief executive officer

Read Bio

Eric is a Founding Board Member of PreciseDx and has stepped in as CEO to drive the execution of the commercialization process. A global CEO and business builder driving shareholder value, he is frequently recruited by healthcare investors for CEO and Board roles to protect and drive their investments. In Eric’s most recent role, he was CEO of AMRA Medical AB, a venture-funded (Pfizer Ventures, Novo Holdings) Software as a Medical Device (SaMD) company using AI/ML technology. AMRA services are based on MRIs with a global reference database for quantitative muscle and fat biomarker measurements for research, pharma, and providers. Prior to AMRA, Eric was an Independent Consultant for Merck’s GHI (Global Health Innovation) Fund, where he conceived and drove a strategy to align Merck’s investment strategy with their commercial requirements across three major divisions to ensure profitable investments and successful corporate collaborations. Previously, Eric was CEO and Board Member for VirtualScopics, a publicly traded (NASDAQ: VSCP) imaging Contract Research Organization sold to BioTelemetry (NASDAQ: BEAT) in 2016, which is currently part of ICON plc. Specifically recruited by Merck, he redefined the research services offering, established an FDA regulatory-compliant structure, and drove sales from $7.5 million to $30 million, enabling the company to sell to BioTelemetry. Eric earned a BA in General Business Administration from Michigan State University. He studied the European Union at the Erasmus University in Rotterdam, the Netherlands.

Ed Sitar

Chief financial officer

Read Bio

Ed Sitar is an experienced financial executive with an extensive healthcare background. He has lead both public and private companies, raising substantial capital and improving operations. Mr. Sitar’s previous roles include serving as the Chief Financial Officer of Variantyx, Inc, 9 Meters Biopharma (Nasdaq:NMTR) and Cancer Genetics, Inc. (Nasdaq:CGIX). Mr. Sitar holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey

Gerardo Fernandez, MD

Chief scientific officer, Co-Founder

Read Bio

Dr. Fernandez is a co-founder and currently Chief Scientific Officer of PreciseDx, in addition to his position as Adjunct Associate Professor in the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at the Mount Sinai Health System. He received his medical degree from Drexel University College of Medicine and completed his residency in anatomic and clinical pathology as well as fellowships in surgical pathology and cytopathology from New York University School of Medicine. Dr. Fernandez has spent the last seven years as Associate Professor at Mount Sinai building and developing the PreciseDx team and platform. Before that, he was in industry as the Medical Director for Roche Tissue Diagnostics’ (Ventana) Digital Pathology group, Vice President for Pathology and Research and Development at Aureon Biosciences, and a Staff Pathologist at Genzyme Genetics, where he specialized in oncologic pathology and tissue biomarkers.

Michael Donovan, MD

Chief medical officer, Co-Founder

Read Bio

Dr. Donovan is a co-founder of PreciseDx, and currently serves as Vice-chair and Professor of Translational Research in the Department of Pathology at the University of Miami. In addition to a previous academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years of experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. Most recently, he has served as Chief Medical Officer of Renalytix, Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc., and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan earned his Bachelor of Science degree in Zoology, a Master of Science degree in Endocrinology, and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his medical degree from the Rutgers New Jersey Medical School.

Ted Diehl

VP, Commercial

Read Bio

Ted M. Diehl is Vice President of Commercial Development at PreciseDx. Diehl is a highly accomplished oncology executive with over 20 years of leadership experience in business development, commercialization, and revenue generation. Prior to joining PreciseDx, Diehl held various executive positions at Massive Bio in New York City, Sema4, IBM Watson Healthcare, Genomic Health, Inc., Sanofi, and TAP Pharmaceutical Products Inc. Diehl graduated from Immaculata University with a Bachelor of Arts in Human Resource Management and in Organizational Dynamics and is earning his masters in Executive Leadership from Liberty University. Additionally, he obtains an annual Oncology/Biotechnology Certification through the NCCN Academy and is a Certified Medical Representative through the CMR Institute, University of Medicine and Dentistry of New Jersey. Through his experience, Diehl has been successful in pioneering oncology market entry for both molecular diagnostic testing and AI utility. His expertise encompasses overcoming the challenges of introducing innovative technologies and creating collaborations between commercial and scientific teams to implement strategies for both commercial success and clinical standards of care.

Shelley Glick

VP, Global Market Access

Read Bio

Shelley Glick is a Global Vice President of Market Access at PreciseDx. Shelley is a seasoned executive in Market Access and Reimbursement Strategy with over two decades of leadership driving coverage and payer strategy in molecular diagnostics, oncology, and precision medicine. She has led successful national access initiatives at Renalytix, Exosome Diagnostics, Genomind, and Myriad Genetics, securing coverage for groundbreaking diagnostic tests and improving access for millions of patients. Shelley brings a deep understanding of payer dynamics, regulatory frameworks, and health economics across both government and commercial landscapes. As a Senior Executive of Reimbursement and Payer Strategy, she has played a central role in securing Medicare reimbursement through Local Coverage Determinations (LCDs), negotiating federal contracts, and leading the design of health economics and outcomes research (HEOR) studies that demonstrated clinical and economic value. Throughout her career, Shelley has been a driving force behind payer engagement, early access programs, and scalable billing policies that align with compliance standards while ensuring patient affordability. Shelley is widely recognized for her ability to translate complex payer requirements into executable strategies, and for building strong, cross- functional teams that deliver results. Shelley earned a Bachelor of Arts in Communication from the University of Colorado. A strategic problem solver and mentor, Shelley is passionate about bridging innovation and access, ensuring patients can benefit from cutting-edge diagnostics that drive better health outcomes.

Vijay Yadav

VP, AI & Technology

Read Bio

Vijay Yadav is Vice President, AI & Technology at PreciseDx, bringing nearly two decades of leadership in data, analytics, and artificial intelligence to the executive team. Vijay’s background includes leadership roles in the life sciences industry, spanning clinical development, manufacturing, operations, supply chain, quality and compliance, and regulatory affairs. Most recently, he led the Advanced Analytics team at Merck, where he spearheaded multiple award-winning, AI-driven innovations. A recognized thought leader in responsible AI, data monetization, and enterprise strategy, Vijay serves on the CDO Magazine Global Editorial Board, highlighting his contributions to the field of data. His industry accolades include publications in leading journals and features on prominent data and AI podcasts. Vijay holds a Master's degree in Computer Science from the Institute of Management Technology, India, and a Master's in Business Administration from the University of Massachusetts, Amherst.

Marni Brisson Tierno, PhD, RN

VP, Medical Affairs

Read Bio

Marni Brisson Tierno, Vice President, Medical Affairs at PreciseDx, brings over 20 years of diverse scientific and clinical experience in oncology within academic, cancer cooperative group and industry environments. She has held senior medical affairs roles at leading oncology diagnostics companies, including Genomic Health, Castle Biosciences, Foundation Medicine, and Illumina. Her expertise includes the design and implementation of clinical research protocols, strategic planning of evidence generation, medical education and messaging initiatives, product launch support, and scientific engagement and collaboration with key stakeholders and professional societies. Her focus lies in advancing precision medicine, with specific expertise in gene expression profiling for early-stage disease and comprehensive genomic profiling across solid tumors. These efforts have supported clinical decision-making and contributed to the integration of molecular diagnostics as the standard of care for oncology patients. Marni earned her PhD in Pharmacology from the University of Pittsburgh and maintains clinical perspective through her training and licensure as a registered nurse.

Trish McClay

Oncointelligence Director

Read Bio

Trish McClay is the OncoIntelligence Director at PreciseDx. She brings more than 30 years of oncology experience in the biotech, pharmaceutical, and diagnostic laboratory industries, with start-up ventures Centocor and Genomic Health, as well as established companies IDEC and RPR/Aventis Pharmaceuticals. Trish brings experience in both solid tumors and hematologic malignancies, in roles including sales, marketing, training, and medical education, with a strong background in the field of breast cancer. As a Product Manager, Trish launched Arcola Laboratories, RPR’s flagship generic division, and brought to market their first two products before transitioning into oncology where she launched Oncaspar®, RPR’s first oncology product for Acute Lymphoblastic Leukemia. She was also part of the original internal launch team that brought Taxotere® to market for breast cancer patients in the United States. Trish assumed sales roles at RPR/Aventis and IDEC, and was responsible for multiple products, including the promotional launches of Taxotere®, Anzemet®, Gliadel®, Rituxan®, and Zevalin®. In 2003, Trish was hired to the inaugural commercial launch team at Genomic Health, a pre-IPO start-up, to introduce the first-in-class Oncotype DX® breast cancer assay in the Northeast Region, which went on to become the standard of care for early-stage breast cancer patients. She went on to launch several additional first-in-class multi-gene assays, for Stage II Colon Cancer, DCIS, and Prostate Cancer, as well as a PAN-Cancer NGS test. Trish earned a Bachelor of Science in Business Administration from Thomas Edison State University in New Jersey. Most recently, she has provided consulting services for two start-up companies in the G.I. and breast oncology arena.

EXTERNAL

Scientific Advisory Board

PreciseBreast powers the process of diagnosis and cancer care planning for everyone.

Carlos Cordon-Cardo, MD

Advisor

Read Bio

Dr. Cordon-Cardo is a co-founder and Chairman of the Advisory Board of PreciseDx, and currently serves as Professor and Chair System-Wide of the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai Health System. From 1987 to 2006 Dr. Cordon-Cardo was a faculty member in the Department of Pathology at Memorial Sloan-Kettering Cancer Center, where he created the Division of Molecular Pathology and served as its first Director; scaling the academic ranks from Assistant to Professor of Pathology at Weill Cornell Medical College, Cornell University. A pioneer of the oncologic molecular pathology discipline, Dr. Cordon-Cardo has helped establish a deeper understanding of the mechanisms of human cancers and new targets for cancer therapeutics, enhancing the vision of personalized medicine. Dr. Cordon-Cardo earned his medical degree from the Autonomous University of Barcelona (1980), and his Ph.D. in Cell Biology and Genetics from Cornell University (1985).

Kevin Fox, MD

Advisor

Read Bio

Past Medical Director of the Rena Rowan Breast Center at the Abramson Cancer Center of the University of Pennsylvania Dr. Fox held the Mariann T. and Robert J. MacDonald Professorship of Breast Cancer Care Excellence for the Perelman School of Medicine at the University of Pennsylvania Dr. Fox was professor of medicine at Penn Medicine, earned his medical degree in 1981 from Johns Hopkins University School of Medicine and completed his internship and residency at Johns Hopkins Hospital. He also completed a fellowship in hematology/oncology at HUP. Dr. Fox is a member of the American Society of Clinical Oncology. Dr. Fox is Board Certified in Internal Medicine and Hematology/Oncology

Reshma Mahtani, DO

Advisor

Read Bio

Chief of Breast Medical Oncology at Baptist Health South, Miami Cancer Institute Dr. Reshma L. Mahtani serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer. Prior to her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and was a member of the editorial board of The Breast Journal. She is Editor-in-Chief for Practice Update. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series Dr. Mahtani is Board Certified in Internal Medicine and Medical Oncology.

Joyce O’Shaughnessy, MD

Advisor

Read Bio

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. Dr. O’Shaughnessy founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. Dr. O’Shaughnessy is Board Certified in Medical Oncology and Internal Medicine.

Stuart Schnitt, MD

Advisor

Read Bio

Chief of Breast Oncologic Pathology for the Dana-Farber/Brigham and Women’s Cancer Center Associate Director of the Dana-Farber Cancer Institute/Brigham and Women’s Hospital Breast Oncology Program co-leader of the Dana Farber Harvard Cancer Center Breast Program Senior Pathologist at Brigham and Women’s Hospital Professor of Pathology at Harvard Medical School.

Joseph A. Sparano, MD FACP

Advisor

Read Bio

Chief of the Division of Hematology and Medical Oncology at Mount Sinai Heath System Deputy Director of the Tisch Cancer Institute. Dr. Sparano holds the Ezra M. Greenspan MD Professorship in Clinical Cancer Therapeutics at Mount Sinai He joined Mt. Sinai in 2021 following a 33-year career at Albert Einstein College of Medicine and Montefiore Medical Center, where he was Professor of Medicine and Obstetrics, Gynecology and Women’s Health, Associate Chairman for Clinical Research in the Department of Oncology, and Associate Director for Clinical Research at the Albert Einstein Cancer Center. Dr. Sparano is the Deputy Chair of the Eastern Cooperative Oncology Group (ECOG) – American College of Radiology Imaging Network (ACRIN) Cancer Research Group and the Early Breast Cancer Trialist’ Collaborative Group (EBCTCG) Steering Committee.